{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:38:27Z","timestamp":1769279907106,"version":"3.49.0"},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1047951120001092_as1\"><jats:title>Background:<\/jats:title><jats:p>Lower respiratory tract infections caused by respiratory syncytial virus can be severe during infancy, which requires admission to the hospital. These infections may be more severe especially in patients with congenital heart disease. Passive immunisation with palivizumab, a monoclonal antibody, is recommended in high-risk infants. We tried to determine the compliance rates, factors affecting compliance, and also other microorganisms responsible for lower respiratory tract infections after palivizumab prophylaxis in these patients.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120001092_as2\"><jats:title>Methods:<\/jats:title><jats:p>We evaluated patients\u2019 compliance to prophylaxis with palivizumab in two consecutive respiratory syncytial virus seasons from pharmacy records. We also investigated factors affecting compliance and the frequency of hospitalisations for lower respiratory tract infections. We investigated the causative microorganisms detected in hospitalised patients.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120001092_as3\"><jats:title>Results:<\/jats:title><jats:p>In this study, 86.7% of the desired number of injections was achieved in 176 patients in two seasons. Out of these, 117 patients (66.4%) received all the doses they were prescribed. Although not statistically significant, compliance to prophylaxis was higher in male patients, cyanotic patients, those who started under 1 year old, and who lived in the city centre. Human metapneumovirus, parainfluenza type 3, and bocavirus were detected in the hospitalised patients.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951120001092_as4\"><jats:title>Conclusion:<\/jats:title><jats:p>Patients with congenital heart disease can survive the period of infancy with less problem by making palivizumab prophylaxis more effective, and awareness about non- respiratory syncytial virus factors may be a guide for the development of new treatments.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1047951120001092","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T09:09:41Z","timestamp":1589879381000},"page":"818-821","source":"Crossref","is-referenced-by-count":3,"title":["Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis"],"prefix":"10.1017","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-7372","authenticated-orcid":false,"given":"Kutay","family":"Sel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1371-8399","authenticated-orcid":false,"given":"Ebru","family":"Aypar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin Nuran","family":"D\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Aliyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-3977","authenticated-orcid":false,"given":"Hakan Hayrettin","family":"Aykan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Karag\u00f6z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dursun","family":"Alehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"S1047951120001092_ref5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"S1047951120001092_ref7","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child."},{"key":"S1047951120001092_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)80040-3"},{"key":"S1047951120001092_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-009-9577-0"},{"key":"S1047951120001092_ref14","volume-title":"Full prescribing information","year":"2008"},{"key":"S1047951120001092_ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000232632.86800.8c"},{"key":"S1047951120001092_ref2","first-page":"63","article-title":"Best practice in the prevention and management of paediatric respiratory syncytial virus infection","volume":"3","author":"Drysdale","year":"2016","journal-title":"Ther Adv Infect Dis."},{"key":"S1047951120001092_ref4","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.139188"},{"key":"S1047951120001092_ref8","unstructured":"8. Committee on Infectious Diseases; American Academy of Pediatrics; Kimberlin, DW , Brady, MT , Jackson, MA , Long, SS . Section 3: Summaries of Infectious Diseases, in Red Book; 2018."},{"key":"S1047951120001092_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32835dce2f"},{"key":"S1047951120001092_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23102"},{"key":"S1047951120001092_ref12","first-page":"303","article-title":"Turkish national respiratory syncytial virus team respiratory syncytial virus epidemiology in Turkey","volume":"47","author":"Kanra","year":"2005","journal-title":"Turk J Pediatr."},{"key":"S1047951120001092_ref13","first-page":"1","article-title":"T\u00fcrkiye\u2019de respiratuvar sinsityal virus enfeksiyonlar\u0131n\u0131n mevsimsel \u00f6zellikleri: iki y\u0131ll\u0131k epidemiyolojik cal\u0131\u015fma","volume":"55","author":"Yurdak\u00f6k","year":"2012","journal-title":"\u00c7ocuk Sa\u011fl\u0131\u011f\u0131 ve Hastal\u0131klar\u0131 Dergisi."},{"key":"S1047951120001092_ref15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18553\/jmcp.2010.16.1.46","article-title":"A systematic review of compliance with palivizumab administration for respiratory syncytial virus immunoprophylaxis","volume":"16","author":"Frogel","year":"2010","journal-title":"J Manag Care Pharm."},{"key":"S1047951120001092_ref16","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000922"},{"key":"S1047951120001092_ref3","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951120001092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T07:36:35Z","timestamp":1615793795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951120001092\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1047951120001092"],"URL":"https:\/\/doi.org\/10.1017\/s1047951120001092","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}